Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women
- PMID: 22972942
- PMCID: PMC3636671
- DOI: 10.1093/gerona/gls177
Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women
Abstract
Background: Medication use is a potentially reversible cause of urinary incontinence (UI). The objective of this longitudinal cohort study was to evaluate whether self-reported UI in community-dwelling older women is associated with the use of different classes of antihypertensive agents.
Methods: The sample consisted of 959 black and white women aged 72-81 years without baseline (Year 1) UI from the Health, Aging, and Body Composition Study. Use of any antihypertensive from 10 drug classes (ie, alpha blockers [central], alpha blockers [peripheral], angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, beta blockers, calcium channel blockers, diuretics [loop], diuretics [potassium-sparing], diuretics [thiazide], and vasodilators) was determined during Year 3 in-person interviews. The number of unique antihypertensive agents used and the standardized daily dosage were also examined. Self-reported UI, operationally defined as leaking urine at least weekly during the previous 12 months, was assessed at Year 4 visits.
Results: A total of 197 women (20.5%) reported UI at Year 4. Although any antihypertensive use, number of agents used, and standardized daily dosage at Year 3 were not associated with UI at Year 4, use of one particular drug class-peripheral alpha blockers (ie, doxazosin, prazosin, and terazosin)-was associated with fourfold greater odds of UI (adjusted odds ratio = 4.47; 95% confidence interval = 1.79-11.21; p = .0014). Further, in post hoc analyses, these odds nearly doubled in those also taking loop diuretics (adjusted odds ratio = 8.81; 95% confidence interval = 1.78-43.53; p = .0076).
Conclusion: In community-dwelling older women, peripheral alpha blocker use was associated with UI, and the odds nearly doubled when used with loop diuretics.
Comment in
-
Re: Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women.J Urol. 2013 Sep;190(3):976-7. doi: 10.1016/j.juro.2013.05.097. Epub 2013 Jun 6. J Urol. 2013. PMID: 23931210 No abstract available.
References
-
- Fantl JA, Newman DK, Colling J, et al. Managing acute and chronic urinary incontinence. Clinical Practice Guideline. Quick Reference Guide for Clinicians, No. 2, 1996 Update Washington, DC: Agency for Health Care Policy and Research; 1996. AHCPR Publication No. 96-0686. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive&part=A32554#A32573. Accessed April 4, 2012
-
- McGrother C, Resnick M, Yalla SV, et al. Epidemiology and etiology of urinary incontinence in the elderly. World J Urol 1998. 16(suppl 1):S3–S9 - PubMed
-
- Ruby CM, Hanlon JT, Fillenbaum GG, Pieper CF, Branch LG, Bump RC. Medication use and control of urination among community-dwelling older adults. J Aging Health 2005. 17 661–674 - PubMed
-
- Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc 2006. 54 405–412 - PubMed
-
- Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs Aging 2008. 25 541–549 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01-AG-62101/AG/NIA NIH HHS/United States
- R01-NR-012459/NR/NINR NIH HHS/United States
- N01-AG-62106/AG/NIA NIH HHS/United States
- K07-AG-033174/AG/NIA NIH HHS/United States
- R01-HS-017695/HS/AHRQ HHS/United States
- N01-AG-62103/AG/NIA NIH HHS/United States
- K12-HS-019461/HS/AHRQ HHS/United States
- T32-AG-021885/AG/NIA NIH HHS/United States
- R56-AG-027017/AG/NIA NIH HHS/United States
- R01 AG034056/AG/NIA NIH HHS/United States
- K07 AG033174/AG/NIA NIH HHS/United States
- P30 AG024827/AG/NIA NIH HHS/United States
- R01 AG027017/AG/NIA NIH HHS/United States
- R01-HS-018721/HS/AHRQ HHS/United States
- R01-AG-027017/AG/NIA NIH HHS/United States
- R01-AG-034056/AG/NIA NIH HHS/United States
- P30-AG-024827/AG/NIA NIH HHS/United States
- R01-AG-028050/AG/NIA NIH HHS/United States
- R56 AG027017/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
